

# IMMUNO-RHEUMATOLOGY

## PUBLICATIONS

- \* Alcobendas R, Rodríguez-Vidal A, Pascual-Salcedo D, Murias S, Remesal A, Diego C, Merino R. Monitoring serum etanercept levels in juvenile idiopathic arthritis: a pilot study. *Clin Exp Rheumatol*. 2016;34(5):955-6. Letter. IF: 2.634; Q3
- \* Almodóvar R, Navarro-Compán V, Fernández-Carballido C, Hernández A, de Miguel E, Zarco P. Differences between familial and sporadic early spondyloarthritis: results from the ESPERANZA cohort. *Clin Exp Rheumatol*. 2016;34(4):575-80. Article. IF: 2.634; Q3
- \* Baron R, Likar R, Martín-Mola E, Blanco FJ, Kennes L, Mueller M, Falke D, Steigerwald I. Effectiveness of tapentadol prolonged release (PR) compared with Oxycodone/Naloxone PR for the management of severe chronic low back pain with a neuropathic component: A randomized, controlled, open-label, phase 3b/4 study. *Pain Pract*. 2016;16(5):580-99. Article. IF: 2.495; Q2
- \* de Hooge M, van den Berg R, Navarro-Compán V, Reijnen M, van Gaalen F, Fagerli K, Landewe R, van Oosterhout M, Ramonda R, Huizinga T, van der Heijde D. Patients with chronic back pain of short duration from the SPACE cohort: which MRI structural lesions in the sacroiliac joints and inflammatory and structural lesions in the spine are most specific for axial spondyloarthritis? *Ann Rheum Dis*. 2016;75(7):1308-14. Article. IF: 12.811; D1
- \* del Río-Martínez P, Navarro-Compán V, Díaz-Miguel C, Almodovar R, Mulero J, de Miguel E. Similarities and differences between patients fulfilling axial and peripheral ASAS criteria for spondyloarthritis: Results from the Esperanza Cohort. *Semin Arthritis Rheu*. 2016;45(4):400-3. Review. IF: 4.498; Q1
- \* Ferreiro-Iglesias A, Montes A, Pérez-Pampín E, Canete JD, Raya E, Magro-Checa C, Vasilopoulos Y, Sarafidou T, Cáliz R, Ferrer MA, Joven B, Carreira P, Balsa A, Pascual-Salcedo D, Blanco FJ, Moreno-Ramos MJ, Fernández-Nebro A, Ordóñez MC, Alegre-Sancho JJ, Narváez J, Navarro-Sarabia F, Moreira V, Valor L, García-Portales R, Márquez A, Martín J, Gómez-Reino JJ, González A. Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis. *Pharmacogenomics J*. 2016;16(2):137-40. Article. IF: 3.815; Q1
- \* Gossec L, Portier A, Landewe R, Etcheto A, Navarro-Compán V, Kroon F, van der Heijde D, Dougados M. Preliminary definitions of 'flare' in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative. *Ann Rheum Dis*. 2016;75(6):991-6. Article. IF: 12.811; D1
- \* Koski JM, Kamel A, Waris P, Waris V, Tarkiainen I, Karvanen E, Szkudlarek M, Aydin SZ, Alasaarela E, Schmidt W, de Miguel E, Mandl P, Filippucci E, Ziswiler H, Terslev L, Ats K, Kurucz R, Naredo E, Balint P, Iagnocco A, Lepojarvi S, Elseoud A, Fouda M, Saarakkala S. Atlas-based knee osteophyte assessment with ultrasonography and radiography: relationship to arthroscopic degeneration of articular cartilage. *Scand J Rheumatol*. 2016;45(2):158-64. Article. IF: 2.667; Q2
- \* Kviatkovsky MJ, Ramiro S, Landewe R, Dougados M, Tubach F, Bellamy N, Hochberg M, Ravaud P, Martín-Mola E, Awada H, Bombardier C, Felson D, Hajjaj-Hassouni N, Logeart I, Matucci-Cerinic M, van de Laar M, van der Heijde D. The minimum clinically important improvement and patient-acceptable symptom state in the BASDAI and BASFI for patients with ankylosing spondylitis. *J Rheumatol*. 2016;43(9):1680-6. Article. IF: 3.15; Q2
- \* López-Isac E, Martín JE, Assassi S, Simeón CP, Carreira P, Ortego-Centeno N, Freire M, Beltrán E, Narváez J, Alegre-Sancho JJ, Fernández-Gutiérrez B, Balsa A, Ortiz AM, González-Gay MA,

- Beretta L, Santaniello A, Bellocchi C, Lunardi C, Moroncini G, Gabrielli A, Witte T, Hunzelmann N, Distler JHW, Riekemasten G, van der Helm-Van Mil AH, de Vries-Bouwstra J, Magro-Checa C, Voskuyl AE, Vonk MC, Molberg O, Merriman T, Hesselstrand R, Nordin A, Padyukov L, Herrick A, Eyre S, Koeleman BPC, Denton CP, Fonseca C, Radstake TRDJ, Worthington J, Mayes MD, Martín J. IRF4 Newly identified as a common susceptibility locus for systemic sclerosis and rheumatoid arthritis in a cross-disease meta-analysis of genome-wide association studies. *Arthritis Rheumatol.* 2016;68(9):2338-44. Article. IF: 6.918; D1
- \* López-Mejías R, Genre F, Remuzgo-Martínez S, González-Juanatey C, Robustillo-Villarino M, Llorca J, Corrales A, Vicente E, Miranda-Fillooy JA, Magro C, Tejera-Segura B, Huaranga MAR, Pina T, Blanco R, Alegre-Sancho JJ, Raya E, Mijares V, Ubilla B, Sánchez MDM, Gómez-Vaquero C, Balsa A, Pascual-Salcedo D, López-Longo FJ, Carreira P, González-Álvaro I, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Ferraz-Amaro I, Castañeda S, Martín J, González-Gay MA. Influence of elevated-CRP level-related polymorphisms in non-rheumatic Caucasians on the risk of subclinical atherosclerosis and cardiovascular disease in rheumatoid arthritis. *Sci Rep-Uk.* 2016;6:31979. Article. IF: 4.259; Q1
  - \* Martín-Mola E, Balsa A, García-Vicuña R, Gómez-Reino J, González-Gay MA, Sanmartí R, Loza E. Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review. *Rheumatol Int.* 2016;36(8):1043-63. Article. IF: 1.824; Q3
  - \* Moots RJ, Balsa A, Wolbink G. Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required. *Ann Rheum Dis.* 2016;75(5):E24. Letter. IF: 12.811; D1
  - \* Navarro-Compán V, Machado PM. Sacroiliac joint radiographic progression - speed and determinants. *Nat Rev Rheumatol.* 2016;12(7):380-1. Editorial Material. IF: 12.188; D1
  - \* Navarro-Compán V, Plasencia-Rodríguez C, de Miguel E, Balsa A, Martín-Mola E, Seoane-Mato D, Canete JD. Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review. *Rheumatology.* 2016;55(7):1188-94. Article. IF: 4.818; Q1
  - \* Navarro-Compán V, Ramiro S, Landewe R, Dougados M, Miceli-Richard C, Richette P, van der Heijde D. Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort. *Ann Rheum Dis.* 2016;75(5):874-8. Article. IF: 12.811; D1
  - \* Nolla JM, Rodríguez M, Martín-Mola E, Raya E, Ibero I, Nocea G, Aragón B, Lizan L, Prades M. Patients' and rheumatologists' preferences for the attributes of biological agents used in the treatment of rheumatic diseases in Spain. *Patient Prefer Adher.* 2016;10:1101-13. Article. IF: 1.798; Q2
  - \* Plasencia C, Wolbink G, Krieckaert CLM, Kneepkens EL, Turk S, Jurado T, Martínez-Feito A, Navarro-Compán V, Bonilla G, Villalba A, Peiteado D, Nuno L, Martín-Mola E, Nurmohamed MT, van der Kleij D, Rispens T, Pascual-Salcedo D, Balsa A. Comparing a tapering strategy to the standard dosing regimen of TNF inhibitors in rheumatoid arthritis patients with low disease activity. *Clin Exp Rheumatol.* 2016;34(4):655-62. Article. IF: 2.634; Q3
  - \* Puig JG, de Miguel E. Hyperuricemia and gout: The impact of ultrasonography. *Med Clin-Barcelona.* 2016;146(2):67-8. Editorial Material. IF: 1.125; Q3
  - \* Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B,

Kouloumas M, Landewe R, Martín-Mola E, Nash P, Ostergaard M, Ostor A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. *Ann Rheum Dis*. 2016;75(1):3-15. Review. IF: 12.811; D1

- \* Torices S, Julia A, Muñoz P, Varela I, Balsa A, Marsal S, Fernández-Nebro A, Blanco F, López-Hoyos M, Martínez-Taboada V, Fernández-Luna JL. A functional variant of TLR10 modifies the activity of NF kappa B and may help predict a worse prognosis in patients with rheumatoid arthritis. *Arthritis Res Ther*. 2016;18:221. Article. IF: 4.121; Q2
- \* Varela H, Villamañán E, Plasencia C, Romero JA, Ruano M, Balsa A, Herrero A. Safety of antitumour necrosis factor treatments in chronic rheumatic diseases: therapy discontinuations related to side effects. *J Clin Pharm Ther*. 2016;41(3):306-9. Article. IF: 1,679; Q3
- \* Ventura-Ríos L, Navarro-Compán V, Aliste M, Linares MA, Areny R, Audisio M, Bertoli AM, Cazenave T, Cerón C, Díaz ME, Gutiérrez M, Hernández C, Navarta D, Pineda C, Py GE, Reginato AM, Rosa J, Saaibi DL, Sedano O, Solano C, Castillo-Gallego C, Falcao S, de Miguel E. Is entheses ultrasound reliable? A reading Latin American exercise. *Clin Rheumatol*. 2016;35(5):1353-7. Article. IF: 2.365; Q3
- \* Ventura-Ríos L, Sánchez-Bringas G, Pineda C, Hernández-Díaz C, Reginato A, Alva M, Audisio M, Bertoli A, Cazenave T, Gutiérrez M, Mora C, Py G, Sedano O, Solano C, de Miguel E. Tendon involvement in patients with gout: an ultrasound study of prevalence. *Clin Rheumatol*. 2016;35(8):2039-44. Article. IF: 2.365; Q3